Patents for A61P 35 - Antineoplastic agents (221,099)
05/2001
05/02/2001CN1293671A Substituted bisindolymaleimides for inhibition of cell proliferation
05/02/2001CN1293663A 2,3,4,5-tetrahydro-1H-[1,4] benzodiazepine-3-hydroxamix acids as matrix metal-protease
05/02/2001CN1293662A Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
05/02/2001CN1293656A Anti-tumour agents
05/02/2001CN1293654A Anti-tumour agents
05/02/2001CN1293570A Pharmaceutical formulations for taxanes
05/02/2001CN1293249A Human transmembrane glycosyl transport factor and its coding sequence
05/02/2001CN1293248A Human shear and adenylation specific factor protein and its coding sequence
05/02/2001CN1293247A Human zinc finger protein and its coding sequence
05/02/2001CN1293207A Fusion protein with improved combining activity to target cell receptor
05/02/2001CN1293205A Target-specific cytotoxin chimeric with short-peptide harmone
05/02/2001CN1293202A Chimeric toxin including modified targeting part
05/02/2001CN1293196A Dibenzylisoquinoline alkaloids and its preparing process and medicinal composition
05/02/2001CN1293195A New polycyclicazaindole compound, its preparation method are medicine composition containing same
05/02/2001CN1293042A Propolis honey and its preparing process
05/02/2001CN1065240C Taxanes having butenyl substituted side-chain and pharmaceutical compositions containing them
05/01/2001US6225494 Trisubstituted phenyl derivatives having retinoid agonist or inverse agonist type biological activity
05/01/2001US6225457 Polynucleotide sequences associated with bacterial proteins; for detection of bactericides
05/01/2001US6225455 Constructs for producing phosphorylated fusion proteins
05/01/2001US6225448 1gG /transferrin receptor fusion protein
05/01/2001US6225353 Method and composition for selectively inhibiting melanoma
05/01/2001US6225340 Administering a dosage comprising 5-amino-2,2-dimethyl-6-(3'-(r,s) amino-4'-hydroxy-butan-1-one)-2,3-dihydro-4h-1-benzopyran-4-on e with carrier to inhibit arthritis
05/01/2001US6225338 As antineoplastic agents and antioxidants
05/01/2001US6225335 3-(4′-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease
05/01/2001US6225328 Adamantyl-substituted retinoids and pharmaceutical/cosmetic compositions comprised thereof
05/01/2001US6225325 Administering n-substituted-1,5-dideoxy-1,5-imino-d-glucitol or galactitol for prophylaxis, therapy, reducing, or reversing multidrug resistance in patient undergoing therapy with chemotherapeutic agent
05/01/2001US6225323 Activated iododerivatives for the treatment of cancer and AIDS
05/01/2001US6225322 4-(6,11-dihydro-5h-cyclohepta(2,1-b:4, 5-b')dipyridin-11-yl)-1-piperidinecarboxylic or sulfonic acid derivatives
05/01/2001US6225320 Treatment of pain, inflammation, migraine, emesis and posttherpetic neuralgia
05/01/2001US6225308 Tissue selective compounds in the treatment of prostate cancer or benign prostate hypertrophy
05/01/2001US6225286 Cell surface protein expressed on human cortical thymocyte and their use
05/01/2001US6225284 Somatostatin peptides
05/01/2001US6225113 Genetically engineered vector for the transcription of heterologous genes in cells
05/01/2001US6225098 UDP-N-acetylenolpyruvyglucosamine reductase
05/01/2001US6225085 Nucleotide and amino acid sequence of leucine-rich surface glycoprotein; diagnosis; prophylaxis; therapy; drug screening; fusion proteins; antigenic peptides; antibodies; recombinant production
05/01/2001US6225042 Culturing genetically engineered, antigen presenting insect cell line so that major histocompatibility class i molecules bound to selected peptide are produced on surface of cell, then contacting with cd8 t cells
05/01/2001US6224912 Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment
05/01/2001US6224883 Supplying to tumor, cancer
05/01/2001US6224879 Genetic engineering
05/01/2001US6224868 Reagent and processes for targeting mutant epidermal growth factor receptors
05/01/2001US6224865 Suppression of inhibitors
05/01/2001CA2195395C Cyclic hexapeptide somatostatin analogues
05/01/2001CA2140624C P53 vaccine
04/2001
04/28/2001CA2324495A1 New 9-(3,5-dimethoxyphenyl)-5,8,8a,9-tetrahydrofuro ¢3',4':6,7!-naphto ¢2,3-d! ¢1,3! dioxol-6(5ah)-one derivatives, their preparation process and pharmaceutical compositions containing them
04/26/2001WO2001029564A1 Protein tyrosine kinase receptor polynucleotides, polypeptides, and antibodies
04/26/2001WO2001029233A2 Chimeric immunogenic compositions and nucleic acids encoding them
04/26/2001WO2001029220A2 Mage-a12 antigenic peptides and uses thereof
04/26/2001WO2001029218A2 Nuclear matrix proteins, polynucleotide sequences encoding them, and their use
04/26/2001WO2001029206A1 Methods of producing differentiated progenitor cells and lineage-defective embryonic stem cells
04/26/2001WO2001029199A1 Methods for using 22045, a human cyclic nucleotide phosphodiesterase
04/26/2001WO2001029193A2 Cell constructs that are suitable for immunotherapy, the production and the use thereof
04/26/2001WO2001029192A2 Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses
04/26/2001WO2001029191A1 Method of in vitro culture of lymphocytes and gene therapy compositions
04/26/2001WO2001029190A1 New lymphocytes, a process for preparing the same and their use in therapeutics
04/26/2001WO2001029178A2 Epo primary response gene 1, eprg1
04/26/2001WO2001029129A1 Highly-neutralized ethylene copolymers and their use in golf balls
04/26/2001WO2001029084A2 Novel human proteins and polynucleotides encoding the same
04/26/2001WO2001029079A1 IMMUNO-INTERACTIVE FRAGMENTS OF THE αC SUBUNIT OF INHIBIN
04/26/2001WO2001029073A1 Methods for improving secondary metabolite production in fungi
04/26/2001WO2001029057A1 Antisense modulation of bcl-6 expression
04/26/2001WO2001029056A1 Tadg-15: an extracellular serine protease overexpressed in carcinomas
04/26/2001WO2001029049A2 Imidazole derivatives as phosphodiesterase vii inhibitors
04/26/2001WO2001029044A1 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
04/26/2001WO2001029043A1 Ucs1025 derivatives
04/26/2001WO2001029042A1 Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
04/26/2001WO2001029026A1 Phenyl- and pyridyl-tetrahydro-pyridines having tnf inhibiting activity
04/26/2001WO2001029025A2 Tyrosine kinase inhibitors
04/26/2001WO2001029023A1 Benzopyranyl guanidine derivatives, process for preparation thereof, and pharmaceutical compositions containing them
04/26/2001WO2001029009A1 4,5-disubstituted-2-aminopyrimidines
04/26/2001WO2001029007A1 Pyrazole derivatives as cannabinoid receptor antagonists
04/26/2001WO2001028993A2 Tyrosine kinase inhibitors
04/26/2001WO2001028595A1 Cobalamin conjugates useful as imaging and therapeutic agents
04/26/2001WO2001028594A2 Tumor detection by imaging and therapy of tumors
04/26/2001WO2001028593A2 Conjugates useful in the treatment of prostate cancer
04/26/2001WO2001028592A1 Cobalamin conjugates useful as imaging agents and as antitumor agents
04/26/2001WO2001028587A2 Magnetic targeted carrier
04/26/2001WO2001028585A1 Novel process for making human papillomavirus virus-like particles with improved properties
04/26/2001WO2001028583A2 Melanoma vaccine and methods of making and using same
04/26/2001WO2001028580A2 Modulation of angiogenesis
04/26/2001WO2001028577A2 Inhibition of cell motility and angiogenesis by inhibitors of the grb2 sh2-domain
04/26/2001WO2001028573A2 Monocyte conditioned medium for cancer treatment
04/26/2001WO2001028557A1 Cannabimimetic indole derivatives
04/26/2001WO2001028550A1 Topical anesthetics useful for treating cancer, autoimmune diseases and ischemia
04/26/2001WO2001028521A2 Liposome formulation of 6,9-bis-[(2-aminoethyl)-amino]benzo[g]isoquinoline-5,10-dione dimaleate
04/26/2001WO2001028498A2 Retro-anandamides, high affinity and stability cannabinoid receptor ligands
04/26/2001WO2001028497A2 Novel bicyclic cannabinoid agonists for the cannabinoid receptor
04/26/2001WO2001028494A2 Nordihydroguaiaretic derivatives for use in treatment of tumors
04/26/2001WO2001028492A2 Polyanhydrides with biologically active degradation products
04/26/2001WO2001009129A3 1h-pirido[3, 4-b]indol-1-one derivatives
04/26/2001WO2001006990A3 Use of etodolac to treat cancer
04/26/2001WO2000077040A3 Human intracellular signaling molecules
04/26/2001WO2000075121A3 Process for preparing 10,11-methanobenzosuberane derivatives
04/26/2001WO2000071723A3 Methods for regulating protein conformation using molecular chaperones
04/26/2001WO2000064486A3 Enzymatically activated polymeric drug conjugates
04/26/2001WO2000063246A3 Compounds and methods for modulating beta-catenin mediated gene expression
04/26/2001WO2000061612A3 Compounds and methods for therapy and diagnosis of lung cancer
04/26/2001WO2000061609B1 Prodrugs of thrombin inhibitors
04/26/2001WO2000056889A3 Secreted and transmembrane polypeptides and nucleic acids encoding the same
04/26/2001WO2000055125A3 N-cyanomethyl amides as protease inhibitors
04/26/2001WO2000047163A3 Use of hyaluronic acid or fragments thereof for regulating hematopoietic differentiation